ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

HRTX vs XLO // NET PROFIT MARGIN

Heron Therapeutics Inc. (NASDAQ) VS. Xilio Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: HRTX 2 — XLO 3
▲ NET PROFIT MARGIN LEADER: HRTX
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (HRTX VS. XLO) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC HRTX XLO SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 73.30% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — -10.78% — TIE /fcf-yield <GO>
Operating Margin -1.60% -60.00% +58.40 HRTX /operating-margins <GO>
Net Profit Margin ACTIVE -12.90% -60.00% +47.10 HRTX /net-margins <GO>
Revenue Growth (YoY) — 180.00% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 0.20 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 2/9 4/9 -2.00 XLO /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 37.6 42.1 -4.50 XLO /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $52.7M $52.8M -$116.6K XLO /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR HRTX REV XLO REV HRTX GROSS % XLO GROSS % HRTX FCF XLO FCF
FY 2025 $154.9M $43.8M 73.3% — -$27.9M -$5.5M
FY 2024 $144.3M $6.3M 73.2% — -$24.2M -$18.4M
FY 2023 $309.7M $221.6M — — -$58.8M -$68.6M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
HRTX // BETA —
XLO // BETA —